The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The key ingredient in blockbuster weight-loss drugs could help people manage a serious liver condition before it becomes life ...

Compounding of another big-selling GLP-1 drug – Eli Lilly's tirzepatide – was blocked in December after ... the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of ...